Copyright © 2021. Inderes Oyj. All rights reserved.
Etsi
Käyttäjätili

Hei!

Luo ilmainen tili jotta voit seurata yrityksiä, osallistua foorumin keskusteluun sekä kommentoida meidän sisältöä. Valitse sinulle sopivin tili.

Oliko sinulla jo tili?

Kirjaudu sisään

Carasent ASA

Analyytikko

Foorumi

Tästä Foorumille

Sisäpiirin kaupat

Nettovaikuttavuus

Artikkeli
Yhtiöjulkaisu
Tiedotteet
CARA: Financial calendar
14.1.
2022 
Financial calendar for Carasent ASA

FINANCIAL YEAR 2021


10.02.2022 - Quarterly Report - Q4


FINANCIAL YEAR 2022

15.07.2022 - Half-yearly Report
30.03.2022 - Annual Report
28.04.2022 - Annual General Meeting

28.04.2022 - Quarterly Report - Q1
26.10.2022 - Quarterly Report - Q3
15.02.2023 - Quarterly Report - Q4



This information is published pursuant to the requirements set out in the
Continuing obligations.
Tiedotteet
CARA: New share capital registered
13.1.
2022 
Reference is made to previous announcement on January 11, 2022, concerning the
issuing of consideration shares in connection with the acquisition of Medrave
Software AB. 

The share capital increase pertaining to the placement is now registered with
the Norwegian Register of Business Enterprises ("Foretaksregisteret"). The new
share capital of the Company is NOK 105,554,537.136  divided into 79,245,148
shares at NOK 1.332 per share.
Tiedotteet
CARA: Carasent ASA completes the acquisition of Medrave Software AB and issues consideration shares
11.1.
2022 
Carasent ASA completes the acquisition of Medrave Software AB and increases the
share capital by issuing consideration shares.

Reference is made to the stock exchange announcement on 15 December 2021 by
Carasent ASA ("Carasent" or the "Company") regarding the Company's acquisition
of Medrave Software AB, including its fully-owned Norwegian subsidiary Medrave
Software AS (together "Medrave"). 

The signed acquisition was subject to customary closing conditions with expected
closing during January 2022.
Muut analyysit
Carasent: Clear cross-selling potential with the new acquisition - Redeye
16.12.
2021

Yesterday evening, Carasent announced the acquisition of Medrave, a market leader within quality improvement software for healthcare practices within primary care and secondary outpatient care. Redeye comments on the news.

Tiedotteet
CARA: Carasent ASA acquires Medrave Software AB - Presentation
16.12.
2021 
Attached please find presentation of the acquisition of Medrave Software AB
Tiedotteet
CARA: Carasent ASA acquires Medrave Software AB. Invitation to webcast 16 December 08:00 CET
15.12.
2021 
December 15, 2021 

Carasent ASA acquires Medrave Software AB - invitation to webcast 16 December
08:00 CET.

Carasent ASA has acquired the Swedish company Medrave Software AB, including its
fully-owned Norwegian subsidiary Medrave Software AS (together "Medrave"), a
market leader in Scandinavia within quality improvement software for healthcare
practices within primary care and secondary outpatient care.

"We are very pleased to have completed this transaction with Medrave.
Tiedotteet
CARA: Major shareholder disclosure in Carasent ASA
10.12.
2021 
Please see attachment on www.newsweb.no
Muut analyysit
Carasent: Building a Software One-Stop-Shop for Private Healthcare - Redeye
6.12.
2021

Redeye comments on Carasent’s Q3 report, house of brand strategy, and the much-anticipated Norwegian launch of Webdoc.

Tiedotteet
Redeye: Carasent - Building a Software One-Stop-Shop for Private Healthcare
6.12.
2021

Redeye comments on Carasent’s Q3 report, house of brand strategy, and the much-anticipated Norwegian launch of Webdoc. We have also taken a deeper look at the Avans Soma acquisition and made some remarks concerning the price and quality of the business.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

Muut analyysit
Carasent Q3’21: First comment - Redeye
27.10.
2021

Carasent’s Q3 report was stable and better than what it appears at face level. Some onboarding delays mask Evimeria’s underlying organic growth, which we believe will be resolved over the next couple of quarters.

Carasent ASA